Email Us

Targeted Medication Guidance for Lung Cancer CapitalBio

This test detects SNV, InDel, CNV and gene rearrangement of 12 genes closely related to lung cancer, covering FDA/NMPA drug instructions, NCCN guidelines recommendations and medication guidance with clear drug targets. It is mainly used for lung cancer targeted medication guidance and drug resistance monitoring.

targeted medication guidance for lung cancer

Features of Targeted Medication Guidance for Lung Cancer

GeneRelated Drugs
ALKCrizotinib, Alectinib, Ceritinib, Brigatinib, Lorlatinib
BRAFDabrafenib + Trametinib, Dabrafenib, Vemurafenib
EGFRGefitinib, Erlotinib, Icotinib, Afatinib, Dacomitinib, Osimertinib, Erlotinib + Ramucirumab, Erlotinib + Bevacizumab
HER2(ERBB2)Ado-Trastuzumab Emtansine
METCapmatinib, Crizotinib
NTRK1/2/3Larotrectinib, Entrectinib
RETSelpercatinib, Pralsetinib, Cabozantinib, Vandetanib
ROS1Entrectinib, Crizotinib, Ceritinib, Lorlatinib

Applicable Population of Targeted Medication Guidance for Lung Cancer

  • For newly diagnosed patients with lung cancer, treatment plans can be formulated according to molecular typing.

  • For patients in need of targeted drugs, targeted drugs can be guided based on mutation information.

  • For drug-resistant patients, drug-resistant mutations can be monitored to guide the adjustment of treatment regimens.

Specification of Targeted Medication Guidance for Lung Cancer

Sample typesVenous blood/Tissue/ Paraffin section
TAT10 days

Contact with Capitalbio
Contact Information
Your Inquiries (Expandable)
Detection Kits/Reagents
Research Services
Biochip Design & Fabrication
Diagnostic Services
Building C, Block 88 Kechuang 6th Street, Yizhuang Biomedical Park, Beijing